Clinical pharmacology of a novel diarylsulfonylurea anticancer agent

LY186641 (diarylsulfonylurea, [DSU]) is a novel anticancer agent because of its unique diarylsulfonylurea chemical structure, broad-spectrum antisolid-tumor activity in preclinical models, presumed novel mechanism of action and preclinical toxicities of methemoglobinemia (Met Hgb) and decreased red...

Full description

Saved in:

Bibliographic Details
Published in:	Journal of clinical oncology Vol. 7; no. 11; p. 1733
Main Authors:	Taylor, C W, Alberts, D S, Ketcham, M A, Satterlee, W G, Holdsworth, M T, Plezia, P M, Peng, Y M, McCloskey, T M, Roe, D J, Hamilton, M
Format:	Journal Article
Language:	English
Published:	United States 01-11-1989
Subjects:	Adult Aged Antineoplastic Agents - administration & dosage Antineoplastic Agents - pharmacokinetics Dose-Response Relationship, Drug Drug Evaluation Humans Middle Aged Neoplasms - drug therapy Sulfonylurea Compounds - administration & dosage Sulfonylurea Compounds - pharmacokinetics Tumor Stem Cell Assay
Online Access:	Get more information
Tags:	Add Tag No Tags, Be the first to tag this record!

Description
Summary:	LY186641 (diarylsulfonylurea, [DSU]) is a novel anticancer agent because of its unique diarylsulfonylurea chemical structure, broad-spectrum antisolid-tumor activity in preclinical models, presumed novel mechanism of action and preclinical toxicities of methemoglobinemia (Met Hgb) and decreased red blood cell (RBC) survival. In this study, the in vitro drug sensitivity of human tumors as well as clinical pharmacology and toxicology of DSU in patients with cancer were examined. DSU was administered orally, daily for 7 days with a 3-week treatment cycle. Dose-limiting toxicities were Met Hgb and RBC hemolysis. The maximum-tolerated dose was found to be 1,200 mg/m2/d for 7 days. In pharmacokinetic studies, DSU was found to have a prolonged serum half-life (approximately 30 hours) and a large area under the plasma disappearance curve (8,883.3 micrograms.hr/mL at 1,200 mg/m2/d). A partial remission was observed in one patient with refractory ovarian cancer. In conclusion, DSU can be safely administered to cancer patients and does display antitumor activity. Potential means of obviating the toxicities of this compound are discussed.
ISSN:	0732-183X
DOI:	10.1200/JCO.1989.7.11.1733